Arizona life science and business leaders as well as guests from across
the country will be on hand to applaud the Rowpar Pharmaceuticals team
for their progress in developing products and protocols that people can
use to promote good oral hygiene and overall health.

Rowpar provides innovative oral health solutions to dental and medical
professionals and to the general consumer, helping people get well and
stay well in North America, Europe, Australia and Asia. Its ClōSYS®
brand is recommended by dentists and hygienists, doctors and nurses, and
is among the top 10% of oral care products in CVS, Walgreens, Walmart
and Amazon nationally with new retailers, new stores and new shelves
being added over the past 18 months.

Its motto is “A Cleaner Mouth, A Healthier You®," connecting oral and
systemic health. Cloralstan® is Rowpar’s patented core technology.
ClōSYS products are proven effective in killing various oral pathogens
associated with plaque, gum diseases and other oral diseases, and for
reducing oral malodor, dry mouth, sensitive mouth, and oral mucositis
resulting from chemotherapy as well. ClōSYS products accomplish this
without impeding the healing process or killing bacteria that are
beneficial to health.

Dr. Perry Ratcliff, one of America's leading periodontists and experts
on dental health and gum disease, and a team of leading dental
professionals created ClōSYS in 1991. During Dr. Ratcliff's 50-plus
years of clinical practice, he discovered that stabilized chlorine
dioxide helped to significantly reduce the harmful bacteria in the
mouths of his patients; this discovery has evolved to the patented
formula Cloralstan®, the active ingredient that makes ClōSYS unique,
safe and effective. Dr. Ratcliff remained active in Rowpar’s development
until 2000.

Originally envisioned as a company selling a boutique product line
exclusively to dentists, today Rowpar competes successfully in the world
of fast-moving consumer goods, nationally and internationally. While a
team of less than a dozen seasoned professionals, Rowpar competes
successfully in a world dominated by firms such as Colgate-Palmolive,
Proctor & Gamble, and GlaxoSmithKline. Breaking new ground, CloSYS
products are dispensed by Novartis with each Afinitor™ (breast cancer
chemo) prescription to counteract medically induced oral sores.

Today James Ratcliff, Ph.D., is the second generation of the Ratcliff
family leading Rowpar. Prior to joining the company as Chairman and CEO
in 2000, Ratcliff worked in higher education administration, assisting
colleges, universities, accrediting agencies, NGOs, and ministries of
education in countries on six continents to assess their programs,
services, policies and practices and to implement new or enhanced
procedures. Jim Ratcliff has been a driving force behind expansion of
the company’s product line and its penetration of global markets.

Since its establishment in 1991, Rowpar has maintained its leadership
position by way of inventing new products and applications and acquiring
patents worldwide.

In the last 18 months, Rowpar was recognized for product excellence and
has expanded both its distribution network and its product line.

In May 2017, ClōSYS® Unflavored Oral Rinse and ClōSYS® Gentle Mint Oral
Rinse became the first mouth rinses to be awarded the American Dental
Association (ADA) Seal of Acceptance for the management of oral malodor,
also known as halitosis and commonly referred to as bad breath. In
addition, ClōSYS® Anticavity Toothpaste and ClōSYS® Fluoride Rinse
received the ADA Seal as anticavity treatments in 2016 and 2017,
respectively.

Rowpar received the ADA Seal, a well-respected symbol of excellence in
dentistry, for four of its products in the past 18 months from the
American Dental Association.

In addition, Rowpar received three awards in the recent past: Proficient
Exporter in May 2017 from Sun Corridor EDGE (Economic Development of the
Global Economy), 2017 Innovation in Oral Healthcare Award for North
America from Corporate LiveWire.com (UK), and AdStudy® Award from Signet
Research Inc.

Oral Health Innovations

In 2016 Rowpar developed and commercialized ClōSYS® Fluoride Rinse,
specially formulated for adults 55+. This is the first oral rinse that
provides a solution to common oral health issues that the growing
elderly population faces.

In addition, Rowpar was granted 10 patents in 2016 and 2017 in USA,
Europe, Canada, Australia, Japan and Mexico.

Embraced by Customers

Rowpar services the dental, healthcare and consumer markets. The company
has become a recognized leader in the focus on overall health through
oral health. The company sells its oral care products throughout the
United States, Australia and Canada at dental offices, retail outlets
and online. In the last 18 months ClōSYS® products have been added to
all stores within the Albertsons and Walmart chains and all CVS Health
stores that include new oral rinses and toothpaste products.

Amazon sales have broken all-time Rowpar sales records in four of the
first five months of 2017. ClōSYS is 5 Star rated by Amazon consumers.
ClōSYS® Unflavored mouth rinse sold at Walgreens now ranks as one of the
top 20 selling items in their entire oral care line of 500+ items.

Rowpar products are sold under the ClōSYS® brand in Australia and the
U.S., under the Dentists' Choice brand in Africa and Asia, and under
private label in Europe and India.

“Successfully developing and delivering consumer-oriented health
products requires more from entrepreneurs than the average consumer
product,” shared Joan Koerber-Walker, president and CEO of AZBio. “It
requires perseverance, a commitment to health innovation, and the
ability to earn the confidence of both healthcare professionals and
consumers. The team from Rowpar provide a great example of how to
succeed in an important and highly competitive market.”

“Rowpar is about more than great oral health products,” shared Jim
Ratcliff. “We have fun and try to delight our customers - because the
greatest contributor to good health is happiness.”

A ceremony honoring Rowpar Pharmaceuticals will take place at the AZBio
Awards on October 11, 2017, at the Phoenix Convention Center.

The AZBio Awards ceremony celebrates Arizona’s leading educators,
innovators and companies. Each year, AZBio honors bioindustry leaders
from across the state of Arizona who are illustrative of the depth,
breadth and expertise of its bioscience industry. The AZBio Awards
ceremony is held annually during Arizona
Bioscience Week. AZBW 2017 was proclaimed by the Arizona Senate
earlier this year. Multiple educational events focused on the value of
life science innovation will take place from October 8, 2017, to October
14, 2017, including the BMES
Annual Meeting in Phoenix. The Biomedical Engineering Society (BMES)
is the world’s leading society of professionals devoted to developing
and using engineering and technology to advance human health and
well-being. Attendees at BMES 2017 in Phoenix are expected to include
nearly 4,000 professional scientists, engineers, researchers and
students from academia and industry who are leaders in biomedical
engineering.

A key component in Arizona’s life science ecosystem, the Arizona
Bioindustry Association (AZBio) is the only statewide organization
exclusively focused on Arizona’s bioscience industry. AZBio membership
includes patient advocacy organizations, life science innovators,
educators, healthcare partners and leading business organizations. AZBio
is the statewide affiliate of the Biotechnology Innovation Organization
(BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance
innovation and to ensure that the value delivered from life-changing and
life-saving innovation benefits people in Arizona and around the world.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.